Covered recipient · General Payments record
LINDSAY G BEDORA
Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner Women's Health
General Payments · PY2021–2022
$701.28
- Reported across 43 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2022 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $280.38 | 17 |
By paying entity
PY2022 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $70.43 | 3 |
| Amgen Inc. | $59.47 | 4 |
| Exeltis, USA Inc. | $42.57 | 3 |
| SCYNEXIS, Inc. | $29.48 | 2 |
| Evofem Biosciences, Inc. | $27.84 | 2 |
| Bayer HealthCare Pharmaceuticals Inc. | $18.08 | 1 |
| Organon LLC | $17.84 | 1 |
| Novo Nordisk AS | $14.67 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2022 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| AbbVie Inc. | $25.09 | 03/24/2022 | Food and Beverage | Undisputed | 01/23/2026 | 910551285 | CMS |
| AbbVie Inc. | $22.38 | 05/19/2022 | Food and Beverage | Undisputed | 01/23/2026 | 910551289 | CMS |
| AbbVie Inc. | $22.96 | 06/13/2022 | Food and Beverage | Undisputed | 01/23/2026 | 910551287 | CMS |
| Amgen Inc. | $16.83 | 01/24/2022 | Food and Beverage | Undisputed | 01/23/2026 | 939613623 | CMS |
| Amgen Inc. | $12.34 | 03/21/2022 | Food and Beverage | Undisputed | 01/23/2026 | 939613619 | CMS |
| Amgen Inc. | $14.84 | 06/01/2022 | Food and Beverage | Undisputed | 01/23/2026 | 939613627 | CMS |
| Amgen Inc. | $15.46 | 08/10/2022 | Food and Beverage | Undisputed | 01/23/2026 | 939613631 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $18.08 | 03/28/2022 | Food and Beverage | Undisputed | 01/23/2026 | 930585911 | CMS |
| Evofem Biosciences, Inc. | $13.05 | 01/05/2022 | Food and Beverage | Undisputed | 01/23/2026 | 900670945 | CMS |
| Evofem Biosciences, Inc. | $14.79 | 07/13/2022 | Food and Beverage | Undisputed | 01/23/2026 | 900670947 | CMS |
| Exeltis, USA Inc. | $14.38 | 01/12/2022 | Food and Beverage | Undisputed | 01/23/2026 | 951322287 | CMS |
| Exeltis, USA Inc. | $15.87 | 02/10/2022 | Food and Beverage | Undisputed | 01/23/2026 | 951318843 | CMS |
| Exeltis, USA Inc. | $12.32 | 07/26/2022 | Food and Beverage | Undisputed | 01/23/2026 | 951316469 | CMS |
| Novo Nordisk Inc | $14.67 | 06/22/2022 | Food and Beverage | Undisputed | 01/23/2026 | 916492113 | CMS |
| Organon LLC | $17.84 | 03/31/2022 | Food and Beverage | Undisputed | 01/23/2026 | 1022259979 | CMS |
| SCYNEXIS, Inc. | $14.74 | 07/11/2022 | Food and Beverage | Undisputed | 01/23/2026 | 905573621 | CMS |
| SCYNEXIS, Inc. | $14.74 | 07/11/2022 | Food and Beverage | Undisputed | 01/23/2026 | 905573623 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022
- Source files
- Dataset page · Bulk file · PY2021 , PY2022
- Generated from
- OP_DTL_GNRL_PGYR2022_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.